Related Experiment Video
Updated: Jun 4, 2026
12:27
A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
Published on: June 8, 2022
Sphingosine 1-phosphate receptor modulator FTY720 suppresses rat experimental autoimmune prostatitis
Z-Y Zhang1, C Zug, H J Schluesener
1Institute of Brain Research, University of Tuebingen, Tuebingen, Germany. zhiyuan.zhang@medizin.uni-tuebingen.de
Scandinavian Journal of Immunology
|February 18, 2011
Summary
FTY720 effectively reduced immune cell infiltration and tissue damage in experimental autoimmune prostatitis (EAP) in rats. This suggests FTY720 may be a promising treatment for inflammatory prostatitis.
Area of Science:
- Immunology
- Pathology
- Pharmacology
Background:
- Experimental autoimmune prostatitis (EAP) is an inflammatory disease mirroring human chronic prostatitis.
- EAP involves prostate-specific autoimmune responses and inflammatory cell infiltration.
Purpose of the Study:
- To investigate pathological changes during rat EAP development.
- To evaluate the therapeutic potential of FTY720 in EAP.
Main Methods:
- Immunohistochemistry was used to analyze immune cell infiltration in rat prostates.
- FTY720, a sphingosine-1-phosphate receptor modulator, was administered to EAP rats.
Main Results:
- Significant accumulation of mononuclear cells (MNCs), T cells, and CD8+ cells occurred by day 11, followed by macrophages.
- FTY720 treatment suppressed inflammatory cell infiltration and reduced prostate tissue disruption.
- Immune cell levels returned to normal by day 35 in untreated EAP rats.
Conclusions:
- FTY720 demonstrates significant therapeutic effects in reducing inflammation and tissue damage in EAP.
- FTY720 is a potential candidate for treating inflammatory prostatitis.
